First shipment of new Optos device made

Retinal imaging company Optos has completed the first shipment of its California device

31 Mar 2015 by Emily McCormick

Retinal imaging company Optos has announced the completion of the first shipments of its new California device.

Described as the second device from its “next generation ultra-widefield (UWF) imaging platform,” the California is a compact table-top retinal imaging tool which is designed to provide greater imaging functionality. It is targeted at the ophthalmology market.

California utilises Optos’s newest imaging modality; indocyanine green angiography (ICG), while maintaining all of its current colour imaging modalities, such as autofluorescence and fluorescein angiography. ICG is used for imaging the choroidal vasculature, which is important for the diagnosis, management and treatment of conditions such as neovascular age-related macular degeneration and disorders with choroidal neovascular membranes.

In addition, the California features a number of software and hardware enhancements, including OptosAdvance which aims to provide users with an easier procedure workflow. Also incorporated is Optos ProView, which enhances image registration for tracking retinal disease development over time and comparison of images across all retinal image modalities.

CEO of Optos, Roy Davis, confirmed: “We have begun shipments of our California devices as planned, demonstrating a tremendous company-wide achievement.

He added: “We have utilised the latest design, manufacturing and software technologies in California and continued our investment in clinical research to support this product launch. The addition of ICG in our newest UWF device provides retinal specialists and ophthalmologists with more imaging tools, allowing them to see and treat retinal pathology more effectively.

“California further supports our entry into the ophthalmology segment and aspiration to make Optomap images a standard of care in this market.


Your comments

You must be logged in to join the discussion. Log in

Comments (0)